drugset / Trial / NCT05116995

Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients

NCT05116995

Phase 4 Unknown 30 enrolled Nova Scotia Health Authority
RandomizedCrossoverSingle-blindTreatment

Summary

The investigators will be comparing the effects of two different drug treatment strategies, in patients with history of a heart attack, on different markers of bleeding and clotting risk. Both treatment strategies are already approved for the indication of improving outcomes in high-risk patients with history of heart attack.

Timeline

Start
2021-11-01
Primary completion
2023-11-01
Completion
2023-11-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rivaroxaban Other / unclassified 2.5 mg
Comparator Ticagrelor Small molecule 60 mg